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1  |  INTRODUC TION
Organ transplantation is a common and successful treatment for 
end-stage organ failure. Over 139 024 solid organs were trans-
planted globally in 2017, an increase of 7.25% on the previous year.1 
The introduction of azathioprine in 1963 made kidney allotrans-
plantation more broadly feasible and the link between immunosup-
pression and increased risk of cutaneous malignancy was identified 
shortly afterwards in Australia.2 Over 80% of organ transplant recip-
ients (OTRs) in Australia3 and 53% of OTR in the United Kingdom4 
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Organ transplant recipients (OTRs) are at increased risk of cutaneous malignancy. 
Skin disorders in OTRs of color (OTRoC) have rarely been systematically assessed. We 
aimed to ascertain the burden of skin disease encountered in OTRoC by prospectively 
collecting data from OTRs attending 2 posttransplant skin surveillance clinics: 1 in 
London, UK and 1 in Philadelphia, USA. Retrospective review of all dermatological 
diagnoses was performed. Data from 1766 OTRs were analyzed: 1024 (58%) white, 
376 (21%) black, 261 (15%) Asian, 57 (3%) Middle Eastern/Mediterranean (ME/M), and 
48 (2.7%) Hispanic; and 1128 (64%) male. Viral infections affected 45.1% of OTRs, and 
were more common in white and ME/M patients (P < .001). Fungal infections affected 
28.1% and were more common in ME/M patients (P < .001). Inflammatory skin disease 
affected 24.5%, and was most common in black patients (P < .001). In addition, 26.4% 
of patients developed skin cancer. There was an increased risk of skin cancer in white 
vs nonwhite OTRs (HR 4.4, 95% CI 3.5-5.7, P < .001): keratinocyte cancers were more 
common in white OTRs (P < .001) and Kaposi sarcoma was more common in black 
OTRs (P < .001). These data support the need for programs that promote targeted 
dermatology surveillance for all OTRs, regardless of race/ethnicity or country of origin.
K E Y W O R D S
cancer/malignancy/neoplasia: melanoma, cancer/malignancy/neoplasia: skin—nonmelanoma, 
clinical research/practice, dermatology, ethnicity/race, immunosuppression/immune 
modulation, infection and infectious agents—fungal, infection and infectious agents—viral
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develop skin cancer within 20 years of transplantation, and the risk 
of cutaneous squamous cell carcinoma (SCC) is reported to be up 
to 250 times that of the general population.3,4 OTRs are also at in-
creased risk of viral, bacterial, and fungal infections.5
While direct toxicities of specific immunosuppressive drugs is 
responsible for some of the skin disorders encountered in OTRs, the 
reduced immune surveillance caused by these drugs is a key driver 
for skin infections and malignancies.6
Primarily because of the increased risk of skin cancers, policy 
makers in both the United Kingdom and United States advocate 
that OTRs should be seen in dedicated surveillance dermatology 
clinics.7-9 Much of the research underpinning this advice has been 
generated in the United States, northern Europe, and Australia and 
has focused on white OTR populations in whom keratinocyte can-
cers are more common. However, evidence from South Africa and 
Saudi Arabia reported Kaposi sarcoma (KS) to occur more frequently 
in nonwhite populations.10-12 Furthermore, few studies have sys-
tematically detailed nonmalignant skin conditions in OTR of color 
(OTRoC).
With global migration rising and access to transplant expanding, 
OTR populations are becoming racially and ethnically more diverse. 
We designed this study in order to evaluate the spectrum of skin 
disease among such diverse OTR populations in the United Kingdom 
and United States. Understanding the consequences of this diversity 
in terms of variation in malignant and nonmalignant posttransplant 
skin disease will improve optimal skin care provision and surveillance 
for all OTRs, regardless of race and skin type.
2  |  MATERIAL S AND METHODS
2.1  |  Patient populations
We performed a review of clinicopathologic data of patients at-
tending posttransplant skin surveillance clinics at 2 large University 
teaching hospitals where universal screening of OTRs is practiced: 
Drexel Dermatology Center for Transplant Patients and the Royal 
London Hospital, Barts Health NHS Trust. Both centers serve ra-
cially and ethnically diverse patient populations.4,13
2.2  |  Data collection
Prospective databases containing all patients seen in the 2 clinics 
from their initiation (1989 in London; 2011 in Philadelphia) to July 
2018 were evaluated and medical records retrospectively searched 
to validate these data. Data recorded included age at transplant, type 
of transplant, and self-reported race/ethnicity. Length of follow-up 
was determined from time of transplant to either last recorded clinic 
appointment (94%) or close of study (6%). Details of skin disease, 
including type of cancer and date of histological diagnosis, were con-
firmed by pathology report when available. Other skin diseases were 
recorded at date of clinical diagnosis.
2.3  |  Statistical analysis
Demographics were compared between each OTR group and be-
tween the 2 centers. The groups were compared using ANOVA for 
continuous and chi-square for categorical variables. Kaplan-Meier 
(KM) curves were generated for skin cancer–free survival after 
transplant with statistical significance assessed by log-rank test. 
Hazard ratios (HRs) with 95% confidence intervals (CIs) for cancer-
free survival were estimated, adjusting for self-reported race, age, 
gender, center, and type of graft organ using a Cox proportional haz-
ard regression model. Odds ratios (ORs) were calculated when sta-
tistically feasible. All applied tests were 2 sided and values of P < .05 
were considered as statistically significant. The statistical analyses 
were conducted on IBM SPSS 25 and R-studio version 3.6.1.
3  |  RESULTS
3.1  |  Demographics
In this study, 1806 OTRs under routine surveillance in both centers 
were identified: 40 were excluded as they were under 18 years old at 
time of transplant. Of the remaining 1766 OTRs, 1257 were from the 
London cohort, and 509 were from the Philadelphia cohort; 1128 
(64%) were male and 638 (36%) were female.
The centers in London and Philadelphia both serve a racially di-
verse cohort of OTRs. There were more white OTRs in the London 
cohort (67.5% vs 34.6%, P < .001), whereas there were a higher 
number of African American/Afro Caribbean/British Caribbean 
OTRs in Philadelphia (47.5% vs 4.4%, P < .001). Although 67.5% of 
the London cohort was white; demographics have changed over 
the past 30 years. In 2019, only 34% of patients on the transplant 
waiting list were white.14 The London cohort was transplanted at 
a younger age than the Philadelphia cohort (median 43 years vs 
60 years, P < .001) and had a longer duration of transplantation (me-
dian 10 years vs 5.9 years, P < .001). Demographics by center are 
presented in Table 1.
Date of transplant ranged between June 15, 1969 and January 
16, 2018; 1596 (90%) of patients received a kidney or simultaneous 
kidney/pancreas transplant; 63 (3.6%) received a liver transplant; 59 
(3.3%) received a lung or heart transplant; and 48 (2.7%) patients 
received more than 1 sequential organ transplant (date of first trans-
plant was considered for statistical analysis).
Of the study population, 1024 (58%) patients were white, 376 
(21%) were black, 261 (14.8%) were Asian (11.3% South Asian, 2.9% 
East Asian, 0.6% Southeast Asian), 57 (3.2%) were Middle Eastern/
Mediterranean (ME/M), and 48 (2.7%) were Latino. Median (inter-
quartile range [IQR]) age at transplantation was 47 (35.7-58) years. 
ME/M patients were transplanted at a younger age than other 
groups (P < .001). Median (IQR) duration of transplantation was 9 (4-
16.6) years. White and ME/M patients had a longer duration of trans-
plantation than black and Latino patients (P < .001). Demographics 
and skin disease diagnoses by race are presented in Table 2.
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3.2  |  Overall burden of disease
There was a high prevalence of skin disease in all patients following 
transplant, regardless of race; 1337 (75.7%) patients were diagnosed 
with at least 1 skin condition. White and ME/M OTRs had the high-
est burden of disease (82% and 84%, respectively) than other groups 
(P < .001).
3.3  |  Skin cancer
Overall, 467 (26.4%) patients were diagnosed with at least 1 cutane-
ous malignancy (including SCC in situ [SCCIS]). Median (IQR) time 
from transplantation to diagnosis of first skin cancer was 8.4 years 
(4-13.5). Patients with skin cancer had a longer duration of transplan-
tation than those who did not have skin cancer (273 vs 176 months, 
P < .001). Skin cancer was diagnosed in 409 (39.9%) of white OTRs, 
higher than black (7.2%), ME/M (12.3%), Latino (12.5%), and Asian 
(6.9%) (P < .001) (Table 2).
We conducted KM analysis for cancer-free survival among the 
racial groups (Figure 1). Compared to white OTRs, all other racial 
groups had a reduced risk of skin cancer (P < .001). Cancer-free 
survival in years (mean ± standard error) was lower in white OTRs 
(18.1 ± 0.6), than black (24.5 ± 0.8), ME/M (32.6 ± 1.9), Latino 
(23.1 ± 1.6), and Asian (34.4 ± 1.5) (P < .001).
We then conducted Cox regression analysis to evaluate the ef-
fects of covariates on the HR of developing skin cancer (Figure 2). 
First, we conducted a univariate Cox regression for white vs non-
white OTRs, which showed higher risk of cancer in white than in 
nonwhites (HR 4.4, 95% CI 3.5-5.7, P < .001). Then we conducted 
multivariate Cox regression, with ethnicity, age at transplant, gen-
der, center, and type of transplant included in the model. With white 
OTRs as the reference group, the rate of cancer was much lower 
in the other groups: black (HR 0.28, 95% CI 0.18-0.43), ME/M (HR 
0.30, 95% CI 0.14-0.63), Latino (HR 0.38, 95% CI 0.16-0.88), and 
Asian (HR 0.15, 95% CI 0.09-0.24). With each 1-year increase in age 
at transplant, the HR increased by 1.05 (95% CI 1.04-1.06) (P < .001). 
There was a trend toward a lower risk of skin cancer in females than 
in males (HR 0.82, 95% CI 0.67-1.00) (P = .051). Patients from the 
London cohort were more likely to be diagnosed with skin cancer 
than the Philadelphia cohort (HR 1.95, 95% CI 1.382-2.75, P < .001). 
OTRs with multiple transplanted organs had a reduced risk of skin 
cancer (HR 0.48, 95% CI 0.238-0.99, P = .046).
The incidence of skin cancers in the nonwhite OTRs was less 
than in the white OTRs, but there was a notable difference in the 
Asian cohort in that, on logistic regression, East Asian OTRs had 
higher OR 5.1 (95% CI 1.8-14.1) for skin cancer compared to South 
Asians (P < .001).
3.3.1  |  Keratinocyte cancers (KC) and premalignant 
skin disease
We observed a total of 1644 invasive SCCs in 255 patients. A total 
of 165 OTRs had multiple (≥2) tumors. SCC affected 246 (24%) of 
the white cohort; 97% of all SCC diagnoses were made in white pa-
tients, higher than in any other group (P < .001). One or more SCCIS 
was observed in 251 of all patients, independent of whether inva-
sive SCC was later diagnosed. We observed a total of 882 basal cell 
carcinomas (BCCs), affecting 255 patients, resulting in an overall 
ratio of 1:1.86 BCC:SCC (1:1.88 in white, 4:1 in ME/M, 1:1 in black 
and Asian). In addition, 137 patients had multiple BCCs. SCCIS and 
BCC also affected white OTRs more than patients from other racial 
groups (P < .001).
Actinic keratoses (AKs) are regarded as SCC precursor lesions, 
but in contrast to SCCIS, less than 0.1% will progress to SCC. Their 
diagnosis is almost always clinical rather than histological.15 For 
these reasons, recording of AK incidence and prevalence was less 
consistent than for SCC, BCC, and SCCIC. We therefore did not in-
clude AK in the final dataset.
3.3.2  |  Melanoma
Eleven invasive melanomas were diagnosed, all of which occurred in 
white patients.
TA B L E  1   Demographics by center
London cohort
Philadelphia 
cohort
P-
value
Age at transplant, y, 
median (IQR)
43.0 (32.0-53.0) 60.0 
(49.0-66.0)
<.001
Period of 
observation
1989-2018 2009-2018
Male 801 (63.7%) 327 (64.2%) .8
Race/ethnicity
White 848 (67.5%) 176 (34.6%) <.001
Black 131 (10.4%) 245 (48.1%)
AA/AC/BC 55 (4.4%) 242 (47.5%)
A/BA 76 (6%) 3 (5.9%)
Middle Eastern 56 (4.5%) 1 (0.2%)
Latino/Hispanic 0 48 (9.4%)
Asian 222 (17.7%) 39 (7.7%)
Duration of 
transplantation 
(y), median (IQR)
10.0 (5.0-19.0) 5.9 (2.2-11.2) <.001
Type of transplant
Kidney or kidney/
pancreas
1224 (97.4%) 372 (73.1%) <.001
Liver 3 (0.2%) 60 (11.8%)
Lung/heart 24 (1.9%) 35 (6.9%)
Multiple organ 6 (0.5%) 42 (8.3%)
Note: P < .05 is statistically significant, ANOVA or chi-square.
Abbreviations: AA/AC/BC, African American, Afro Caribbean, British 
Caribbean; A/BA, African, British African.
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3.3.3  |  Kaposi sarcoma (KS)
KS was more common in the black cohort, with 13 of the total 16 cases 
being diagnosed in black African OTRs (P < .001), all of whom were 
born in sub-Saharan Africa. All cases except 1 were diagnosed in the 
London cohort. Median (IQR) time from transplantation to onset of KS 
was 15 (6-36) months.
3.3.4  |  Other skin cancers
Twenty-eight cutaneous appendageal tumors (AT) were diagnosed 
and included 12 porocarcinomas, 9 sebaceous carcinomas, 2 squa-
mous eccrine ductal carcinomas, 2 microcystic adnexal carcinomas, 
and 1 each of eccrine nodular carcinoma, apocrine adenocarci-
noma and sweat duct carcinoma. Two cases of Merkel cell carci-
noma (MCC) and 2 cases of dermatofibrosarcoma protuberans were 
diagnosed. Although affecting predominantly white patients, there 
were no significant differences in disease incidence between races.
3.4  |  Nonmalignant skin disease
Nonmalignant dermatoses were common in all patients (Table 3); 
1236 (70%) of patients were diagnosed with at least 1 condition. 
Bacterial infections were excluded from the analysis, as they usually 
occur acutely and were often treated in the community.
3.4.1  |  Viral infections
White and ME/M patients had a higher incidence of viral infections 
(P < .001). Viral warts were common (737 cases, 41.7%), and affected 
white OTRs more than other groups (P < .001). The presence of viral 
F I G U R E  1   Posttransplant skin cancer (including squamous cell carcinoma in situ)–free survival by race, time in years
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0.25
0.50
0.75
1.00
0 10 20
 Time After Transplant, y
Pe
rc
en
ta
ge
 o
f P
op
ul
at
io
n 
Fr
ee
 o
f S
ki
n 
C
an
ce
r
Ethnicity
White
Black
Middle Eastern
Hispanic/Latino
Asian
Posttransplant Skin Cancer Free Survival
1024 431 124
376 97 19
57 27 12
48 20 7
261 101 38Asian
Hispanic/Latino
Middle Eastern
Black
White
0 10 20
 Time After Transplant, y
E
th
ni
ci
ty
Number at risk
6  |    KENTLEY ET aL.
warts was associated with an increased incidence of both invasive 
SCC and SCCIS (P < .001). Other infections included herpes simplex 
virus (HSV) (59 cases, 3.3%), herpes zoster virus (HZV) (49 cases, 
2.8%), varicella zoster virus (VZV) (6 cases, 0.3%), and molluscum 
contagiosum (28 cases, 1.6%).
3.4.2  |  Fungal infections
The overall incidence of fungal infections was higher in ME/M pa-
tients than in other racial groups (P < .001). Pityriasis versicolor 
(PV) (165 cases, 9.3%) occurred most frequently in Asian OTRs 
(P < .001). Onychomycosis (194 cases, 11%) was more common in 
the ME/M group (P < .001). Tinea pedis (217 cases, 12.3%) was 
diagnosed more frequently in black OTRs (P < .001), whereas non-
pedal tinea (63 cases, 3.6%) was more common in ME/M and Asian 
OTRs (P < .001).
3.4.3  |  Inflammatory skin disease
We observed 135 cases of dermatitis (7.6%): this included cases 
diagnosed clinically or histologically as atopic, allergic contact, irri-
tant contact, dyshidrotic, stasis, asteatotic, or nummular dermatitis. 
Dermatitis was most common in black OTRs (P < 0001). Overall inci-
dence of psoriasis was low (35 patients, 1.4%). Acneiform eruptions 
(AEs) were recorded in 305 patients (17.3%). Overall, black OTR had 
the highest incidence of inflammatory skin disease (P < .001).
3.4.4  |  Miscellaneous skin disease
We observed 281 cases of multiple (≥5) sebaceous hyperplasia (SH) 
(15.9%), with the highest incidence in white and ME/M patients 
(P < .001). Frequencies of other skin conditions were too low to un-
dertake comparative statistical analysis.
4  |  DISCUSSION
This international study has shown a high incidence of cutaneous dis-
ease in OTRs of all races. Although the race-specific risk of KC and 
KS has been well documented, the incidence of other skin disease 
has not been fully explored by previous studies. Immunosuppression-
associated reductions in cell-mediated immunity led to increased risk 
of infection: fungal infections are more common and there is reduced 
control of viral replication with consequent increased incidence of viral 
infections and virally driven cancers such as KS, MCC, anogenital SCC, 
and potentially cutaneous SCC. In addition, immunosuppressants act 
synergistically with ultraviolet radiation (UVR) to promote carcinogen-
esis, both by impairing recognition and elimination of malignant cells 
and also through direct carcinogenic effects.6
F I G U R E  2   Forest plot of multivariate analysis of hazard ratios for developing skin cancer using a Cox proportional hazard regression 
model
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The current pandemic of coronavirus 2019 (COVID 19) 
caused by severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) poses a new threat to OTRs. Although cutaneous 
manifestations of COVID-19 are recognized, there have been no 
reports to date specifically related to OTRs. In addition, while 
the higher rates of intensive care admission and death in OTRs 
support the importance of the current recommendation for 
“shielding,”16,17 there are also concerns that this may result in 
delayed diagnosis and treatment of significant cutaneous infec-
tions and malignancy.
4.1  |  Skin cancer risk factors
Our study confirms that white OTRs have the highest risk of skin 
cancer.18,19 However, we also found the rate of skin cancer in OTRoC 
to be more than double that previously reported (6.9%-12.5% vs 
0%-5%).20-23 The overall median time to onset of skin cancer was 
8.4 years. This was shortest for black patients, mainly because the 
time to diagnosis was shortest for KS, although this did not quite 
reach significance (P = .059).
The HR for skin cancer in the London cohort was almost dou-
ble that of the Philadelphia cohort (1.95), even when adjusting for 
covariates including race and duration of transplantation. Reasons 
for this are unclear and our analysis is unable to exclude the possibil-
ities that this may relate to differences in skin phototype, cumulative 
lifetime UVR exposure, or differences in immunosuppressive drug 
regimens used in the respective centers.
We observed a trend toward reduced risk of skin cancer in fe-
male OTRs. Male sex has previously been reported as a risk factor 
for skin cancer in OTRs.24 This may relate, in part, to photoprotec-
tive behavior and occupational UVR exposure.25,26
Multiorgan transplant recipients appeared to have a reduced risk 
of skin cancer in this study, though the CI was wide. The reasons for 
this are unclear.
4.1.1  |  Keratinocyte cancers and premalignant 
skin disease
Invasive SCC was the most common cancer in OTRs. UVR is the 
main driver for the increased incidence of SCC and BCC observed 
in OTRs through its mutagenic and immunosuppressive effects.5,17 
Additional cofactors include direct carcinogenic effects of immuno-
suppressive medications (including azathioprine and cyclosporine), 
other medication often used posttransplant (such as voriconazole) 
and human papillomavirus (HPV) infection.6,27,28 Consistent with 
the key role for UVR, we observed the highest incidence in white 
patients with lighter skin phototypes.29 When subgroup analysis 
of the Asian cohort was performed, we observed an OR of 5.1 for 
East Asians developing skin cancer when compared to South Asians, 
likely reflecting known differences in Fitzpatrick skin phototype be-
tween these populations.30
SCC rates in the general population have been rising, result-
ing in a BCC:SCC ratio of around 2.5:1 in the United States in 
2018.31 This ratio is reversed in OTRs.32 We observed a ratio of 
TA B L E  3   Infectious and inflammatory skin disease by race
Condition
Race or ethnic group
P-
value
All 
(n = 1766)
White (n = 1024, 
58%)
Black (n = 376, 
57%)
ME/M (n = 57, 
3.2%)
Latino/Hispanic 
(n = 48, 2.7%)
Asian 
(n = 261, 
14.8%)
Viral infections
Viral warts 737 (41.7%) 532 (52%) 74 (19.7%) 28 (49.1%) 8 (16.7%) 95 (36.4%) <.001
HSV 59 (3.3%) 39 (2.8%) 11 (2.9%) 3 (5.3%) 1 (2.1%) 5 (1.9%) .49
HZV 49 (2.8%) 31 (3%) 12 (3.2%) 1 (1.8%) 0 5 (1.9%) .6
VZV 6 (0.3%) 4 (0.4%) 2 (0.5%) 0 0 0 .7
Molluscum contagiosum 28 (1.6%) 19 (1.9%) 3 (0.8%) 0 0 6 (2.3%) .3
Fungal infections
Pityriasis versicolor 165 (9.3%) 98 (9.6%) 15 (4%) 13 (22.8%) 0 39 (14.9%) <.001
Onychomycosis 194 (11%) 120 (11.7%) 26 (6.9%) 13 (22.8%) 1 (2.1%) 34 (13%) <.001
Tinea pedis 217 (12.3%) 106 (10.4%) 65 (17.3%) 8 (14%) 9 (18.8%) 29 (11.1%) .006
Tinea (non-pedal) 63 (3.6%) 32 (3.1%) 9 (3.4%) 5 (8.8%) 2 (4.2%) (155.7%) .04
Inflammatory conditions
Dermatitis 135 (7.6%) 65 (6.3%) 43 (11.4%) 2 (3.5%) 7 (14.6%) 18 (6.9%) .005
Psoriasis 25 (1.4%) 16 (1.6%) 4 (1.1%) 0 2 (4.2%) 3 (1.1%) .4
Acneiform eruption 305 (17.3%) 158 (15.4%) 75 (19.9%) 11 (19.3%) 5 (10.4%) 56 (21.5%) .055
Note: P < .05 is statistically significant, chi-square.
Abbreviations: HSV, herpes simplex virus; HVZ, herpes zoster virus; ME/M, Middle-Eastern/Mediterranean; VZV, varicella zoster virus.
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1:1.86 (882:1644), but this reversed ratio was only observed in 
white OTRs. Studies from Spain and Italy have shown BCCs to 
be more common than SCCs in Mediterranean OTRs.33,34 Darker 
skin phototypes may therefore provide greater protection against 
SCC than BCC.
4.1.2  |  Melanoma
Incidence of melanoma in OTRs is reported to be 2-3 times that of 
the general population.35 It disproportionately affects white popu-
lations, and no OTRoC developed invasive melanoma in this study, 
although the small numbers of cases meant that this did not reach 
significance.36
4.1.3  |  Kaposi sarcoma
Most posttransplant KS is the result of reactivation of latent 
human herpesvirus 8 (HHV8), possibly as a consequence of immu-
noparesis following induction and maintenance immunosuppres-
sion, which allows uncontrolled HHV8 replication.37 Incidence is 
reported to be 500 times higher in OTRs and reflects the sero-
prevalence of HHV8 which is >50% in sub-Saharan Africa, and <5% 
in northern Europe and America.38 Thus, KS was more common in 
black OTRs in the London cohort, the majority of whom originated 
from HHV8-endemic regions of sub-Saharan Africa. In contrast, 
most black patients in the Philadelphia cohort originated from the 
United States and their KS rates were not increased. The 1 patient 
diagnosed with KS in the Philadelphia cohort was also born in sub-
Saharan Africa. Median time to diagnosis of KS was 15 months. 
This is shorter than for other skin cancers and a consequence of 
reactivation of latent rather than acquired HHV8 infection driving 
this malignancy.39-41
4.1.4  |  Other skin cancers
ATs are rare in the general population; however, the standard inci-
dence ratio for ATs in OTRs is reported as 40.42,43 We observed 28 
ATs in our study, a higher prevalence than expected in the general 
population. The majority occurred in white OTRs. Although both 
cyclosporine and azathioprine have been implicated in sebaceous 
tumor development,44,45 the pathogenesis of many ATs is not well 
understood, and UVR, immunosuppression, and viral pathogens 
may all be contributory.46 The incidence of MCC is reported to be 
24 times higher in OTRs, and we observed 2 cases of MCC in our 
study, both in white OTRs.47 Impaired T cell function and UVR are 
proposed to drive unregulated transcription of causative Merkel cell 
polyomavirus (MCPyV) and MCC pathogenesis.47 Seroprevalence 
of MCPyV in the general population is reported to be high (60%-
81%) in studies conducted across Europe, China, and Africa.48-51
4.2  |  Nonmalignant skin disease
4.2.1  |  Viral infections
Viral warts are the most common cutaneous infection in OTRs, 
as confirmed in our study.52,53 The overall rate of clinical HPV 
infection was 42% and white OTRs were the most affected. 
Reduced UVR susceptibility and differences in cellular struc-
ture of the dermis and epidermis may play a role in racial sus-
ceptibility to HPV.54 We also observed that patients diagnosed 
with viral warts had a higher incidence of both SCCIS and in-
vasive SCC. Previous studies have indicated that OTRs have an 
increased HPV diversity, multiplicity, and viral load, and this is 
associated with an approximately 2-fold increased risk of SCC.55 
In addition, the high burden of HPV infection in all races should 
also alert clinicians to an increased risk of HPV-driven SCC in 
the anogenital region, to which OTRoC appear to be dispropor-
tionately affected.6,20,56
We observed apparently low rates of both HSV (3.3%) and HZV 
(2.8%) when compared to the literature. Both HSV and HZV occur 
early in the posttransplant period due to reactivation of latent virus 
on introduction of immunosuppression, and may be under-reported 
in this study due to the acute and transient nature of infection.52,57-59 
Molluscum contagiosum, caused by DNA poxvirus, was also uncom-
mon (1.6%) but consistent with previous studies reporting rates of 
up to 3%.52,60
4.2.2  |  Fungal infections
OTRs have fewer Langerhans cells in the epidermis, and chronic cor-
ticosteroid therapy results in thickening of the stratum corneum and 
delayed desquamation; both of which may be contributory in devel-
oping superficial fungal infections.61,62
Overall incidence of fungal infections was higher in ME/M 
OTR than any other racial group in our study. Case-control stud-
ies have found that PV was the most common superficial mycosis 
observed in OTR with a prevalence of 18%-34%.63,64 We observed 
an increased incidence of PV in Asian OTR. Studies in tropical 
countries have reported prevalence up to 50%, while those per-
formed in Scandinavia report a prevalence of only 1%.65-68 This 
disparity may be the result of varying temperature and humidity 
levels providing a favorable environment for yeasts. However, it 
is also possible that PV is more readily diagnosed in darker skin as 
the associated hypopigmentation is clinically more prominent than 
in lighter skin types.
Onychomycosis has been reported to affect OTRs more fre-
quently than matched controls.63,69 Onychomycosis was most com-
mon in the ME/M cohort, whereas tinea pedis was most common in 
black patients. Dermatophyte infection affecting areas other than 
the feet were more common in ME/M and Asian OTR. The reasons 
for this are not clear.
    |  9KENTLEY ET aL.
4.2.3  |  Inflammatory skin disease
Most inflammatory dermatoses, such as dermatitis and psoriasis, 
are uncommon in OTRs due to the immunosuppressive effects of 
chronic antirejection therapy, and the rates that we observed were 
lower than those reported in the general population.70-73 However, 
OTRs frequently develop drug-induced AEs following transplan-
tation. Acne may be caused by corticosteroids, cyclosporine, my-
cophenolic acid agents, and sirolimus.74 Patients originating from 
high-incidence countries receive antituberculous prophylaxis with 
isoniazid for at least 1 year posttransplant, which is well known to 
provoke AEs.75,76 We observed increased incidence of dermatitis in 
black OTRs. Previous epidemiological studies of the general popula-
tion have shown increased incidence of atopic dermatitis in African 
American and British Caribbean children in both the United States 
and London.77,78
4.2.4  |  Miscellaneous skin disease
We identified multiple SH in 15.9% of our cohort, consistent with 
previous studies that have reported SH in 15%-30% of OTRs, com-
pared with 1% of age- and sex-matched controls. However, previous 
studies have not evaluated racial differences in SH prevalence: we 
saw the greatest incidence in white OTRs, but other races were also 
affected. Multiple SH is appears to occur most commonly in male 
OTRs treated with cyclosporine, a highly lipophilic molecule that 
may directly influence pilosebaceous unit architecture.79,80
4.3  |  Strengths and limitations
The strengths of this study include the racial diversity of subjects, 
comprehensive data analysis and long follow-up period.
We acknowledge a number of limitations. A major confounder 
of this study is the inevitable variability of immunosuppressive 
regimens both between centers as well as between patients, and 
within the same patient over the duration of the study period. 
In addition, the influence of an “era effect”—that is, the effect 
of changes in immunosuppressive regimens used over the time-
span of this study (1989-2018) may also be relevant. OTRs trans-
planted pre-1984 received azathioprine and corticosteroids as 
a standard maintenance immunosuppressive regimen, and after 
1984 cyclosporine was introduced. From the late 1990s, azathi-
oprine was largely replaced with mycophenolate mofetil, tacro-
limus was used as an alternative calcineurin inhibitor and mTOR 
inhibitors were introduced.81 There is evidence that azathioprine 
may be associated with an increased risk of SCC when compared 
to newer antimetabolites such as mycophenolic acid agents and 
mTOR inhibitors are associated with a lower risk.81,82 We have 
previously assessed the potential impact of such “era effects” on 
skin cancer risk in the London cohort and found no significant 
era effect at least for transplantation pre-1985 vs 1985-2000 
(P-value for trend .895).4 However, in view of these confounding 
factors, and also given the inherent challenge of assessing indi-
vidual immunosuppressive burden, we did not analyze in detail 
the association between immunosuppressive drug regimens and 
skin disease in the current study. Nonetheless, we acknowledge 
that such differences may have contributed to our observed 
patterns of skin disease susceptibility.83 The impact of immuno-
suppressive drug regimens on inflammatory and infective skin 
disease is also uncertain and is a potentially important risk factor 
to evaluate in future prospective studies.
Another potential confounder in this study is the self-report-
ing of race, which is recognized to be an inaccurate predictor of 
Fitzpatrick skin phototype.84 The latter influences susceptibility to 
UVR and skin cancer risk but was not reported in this study.
The inherent limitations of a retrospective study that is not 
strictly population-based further limit interpretation of the find-
ings of our study. In particular, the acute nature of many bacterial 
and some viral infections meant that these were not systemati-
cally and fully recorded, particularly when diagnosed and treated 
in the community. A future prospective, population-based 
case-controlled study would strengthen the evidence provided 
by these data.
5  |  CONCLUSIONS
All racial groups are at risk of developing skin disease, but the nature 
and timing of these disorders vary. The patterns of susceptibility to skin 
disease in OTRs of different racial groups identified in this study will 
provide important evidence for rationalizing design of targeted derma-
tology surveillance programs. These data will also inform development 
of tailored education resources for patients and health care providers 
for both recognition and optimal management of skin conditions en-
countered following solid organ transplantation across all racial groups.
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